在过度活动的膀对抗胆固醇药物治疗不耐药的患者中,神圣穿皮电神经刺激的有效性:一项前性的多中心研究
M Coronas Soucheiron1, I Casal Beloy2, F N Villalón Ferrero3
1Pediatric Surgery Department. Hospital Sant Joan de Déu. Barcelona (Spain).
概括
圣经经皮电神经刺激 (S-TENS) 有效地治疗抗胆固醇药物耐药的儿童的过度活性膀 (OB). 这种安全的短期治疗显著改善了白天的尿路症状,并减少了排泄频率.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 儿科泌尿外科 儿科泌尿外科
- 神经调节是一种神经调节.
背景情况:
- 过度活跃的膀 (OB) 显著影响儿童的生活质量.
- 抗胆固醇药物 (Achs) 是一种常见的第一线治疗OB.
- 一部分患者仍然对Achs耐药,需要替代疗法.
研究的目的:
- 评估神经穿皮电动神经刺激 (S-TENS) 的疗效和安全性,用于患有OB的儿科患者.
- 评估S-TENS作为抗胆固醇药物耐药患者的治疗选择.
主要方法:
- 一项前性多中心研究包括66名儿科患者 (5-15岁) 患有抗Achs.
- 在三个月的时间里,S-TENS 进行了治疗.
- 使用空白日历和儿科下尿道症状得分 (PLUTSS) 追踪症状进展,重点关注白天症状 (LUTS变量).
主要成果:
- S-TENS显著降低了PLUTSS得分 (19.1至9.5) 和LUTS变量 (13.1至4.8) (p<0.001).
- 治疗减少了排尿频率 (8.5至6.4),增加了排尿量 (214毫升至258毫升) (p<0.001).
- 尿是唯一没有改善的症状;并发症率很低 (3%).
结论:
- S-TENS证明了儿童OB患者的短期有效性和安全性,这些患者对Achs.
- 需要进一步的研究来确定长期疗效和复发率.
相关概念视频
01:19Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...